The objective of the RADIANCE II Pivotal study is to demonstrate the effectiveness and safety of the Paradise System in subjects with Stage 2 hypertension on 0-2 medications at the time of consent. Prior to randomization, subjects will be hypertensive in the absence of hypertension medication.
Contact phoneSparrow Clinical Research Institute 517.364.5760
Principal investigatorJoel Cohn, M.D., FACC
Trial CategoryHeart & Vascular